| Filed On | Filing |
|---|---|
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial |
| 11 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will beco... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient administration |
| 22 Jul 2026 |
8-K: Other Events
Artiva Biotherapeutics, Inc. (the “Company”) today announced that the expected date for the Company’s 2026 annual meeting of stockholders (the “Annual Meeting”) is September 8, 2026, which is more than 70 days after the one-year annivers... |
| 19 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 08 May 2026 |
8-K: Other Events
Introductory. Artiva Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 23,871,526 shares of its common stock... |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition
Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 |
| 24 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 19 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Over 100 patients treated with AlloNK across autoimmune and oncology indications |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis |
| 25 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will beco... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies and systemic sclerosis |
| 24 Mar 2025 |
8-K: Results of Operations and Financial Condition
Initial data for AlloNK® from autoimmune program expected H1 2025 |
| 29 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases |
| 22 Oct 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 21, 2024, the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Alison Moore, Ph.D. as (i) a Clas... |
Loading...